近日,复星医药发布2024年业绩报,报告期内,该公司实现营业收入410.67亿元,同比下降0.80%;归属于母公司股东的净利润为27.70亿元,同比增长16.08%。值得关注的是,2024年该公司的研发费用为36.44亿元,同比下降16.15%。这一举措短期内可能提升财务表现,但长期来看,是否会对公司的核心竞争力和创新能力产生影响仍有待观察。业内人士指出,面对医药行业的现状,医药企业的竞争日益加剧...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.